Serbian opposition lawmakers threw smoke grenades and tear gas inside parliament on Tuesday to protest against the government ...

Notably, off-label tenecteplase had already become the preferred thrombolytic for acute ischemic stroke before the expanded ...

Research predicts stroke deaths may rise 50% globally by 2050, with younger people increasingly affected. Learn effective ...

Discover how hypertension, diabetes, atrial fibrillation, high cholesterol, and obesity increase stroke risk, and learn ...

For patients with acute ischemic stroke (AIS) whose symptoms began 4.5 to 24 hours earlier, alteplase is associated with a higher percentage of patients achieving a score of 0 or 1 on the modified ...

According to Roche subsidiary Genentech, which announced the label expansion on Monday, TNKase is the first new drug for ...

In 2023, Roche said it was removing TNKase for stroke from its phase 3 programmes after a readout of the TIMELESS trial, but ...

Genentech has had the lone medicine on the market for the acute treatment of stroke. | Over nearly the last three decades, ...

February is American Heart Month. And what better time to talk about heart health? Did you know heart disease claims a life ...

Genentech announced that the U.S. Food and Drug Administration has approved TNKase, a thrombolytic or clot-dissolving agent, for the treatment ...

Women with one or more gynecological disorders had higher risk of heart disease and clogged arteries affecting either their ...

Smoking more than doubles the risk of unexplained strokes among younger adults, a new study warns. And heavy smoking is even ...